EA037698B1 - Композиции, содержащие короткие пептиды, полученные из pedf, и их применение - Google Patents

Композиции, содержащие короткие пептиды, полученные из pedf, и их применение Download PDF

Info

Publication number
EA037698B1
EA037698B1 EA201990885A EA201990885A EA037698B1 EA 037698 B1 EA037698 B1 EA 037698B1 EA 201990885 A EA201990885 A EA 201990885A EA 201990885 A EA201990885 A EA 201990885A EA 037698 B1 EA037698 B1 EA 037698B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pdsp
peptide
cells
stress
mice
Prior art date
Application number
EA201990885A
Other languages
English (en)
Russian (ru)
Other versions
EA201990885A1 (ru
Inventor
Куаньинь Карен Линь
Йоу-Пин Тсао
Тсун-Чуань Хо
Фрэнк Вэнь-Чи Ли
Original Assignee
Брим Байотекнолоджи, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Брим Байотекнолоджи, Инк. filed Critical Брим Байотекнолоджи, Инк.
Publication of EA201990885A1 publication Critical patent/EA201990885A1/ru
Publication of EA037698B1 publication Critical patent/EA037698B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EA201990885A 2016-10-07 2017-08-24 Композиции, содержащие короткие пептиды, полученные из pedf, и их применение EA037698B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662405522P 2016-10-07 2016-10-07
PCT/US2017/048340 WO2018067244A1 (en) 2016-10-07 2017-08-24 Compositions comprising pedf-derived short peptides and uses thereof

Publications (2)

Publication Number Publication Date
EA201990885A1 EA201990885A1 (ru) 2019-08-30
EA037698B1 true EA037698B1 (ru) 2021-05-12

Family

ID=61831898

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990885A EA037698B1 (ru) 2016-10-07 2017-08-24 Композиции, содержащие короткие пептиды, полученные из pedf, и их применение

Country Status (10)

Country Link
US (1) US11760784B2 (enExample)
EP (1) EP3596104A4 (enExample)
JP (2) JP7573967B2 (enExample)
KR (2) KR20230169375A (enExample)
CN (1) CN110312732A (enExample)
AU (2) AU2017340245B2 (enExample)
EA (1) EA037698B1 (enExample)
IL (1) IL265796B2 (enExample)
TW (1) TWI878203B (enExample)
WO (2) WO2018067244A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL277689B2 (en) * 2018-04-08 2024-12-01 Brim Biotechnology Inc Application of pedf-derived short peptides in tendon healing
US20210221862A1 (en) * 2018-04-08 2021-07-22 Brim Biotechnology, Inc. Application of pedf-derived short peptides in the treatment of osteoarthritis
EP3773493A4 (en) * 2018-05-04 2022-03-30 Brim Biotechnology, Inc. PEDF DERIVED PEPTIDES TO PROMOTE MEIBOMIUS GLAND REGENERATION AND THEIR USES
CN111632128B (zh) * 2019-02-14 2022-07-05 三凡生技研发股份有限公司 短链胜肽组合物在预防或治疗干眼症的应用
TWI759610B (zh) * 2019-06-27 2022-04-01 晶碩光學股份有限公司 具有角膜修護功能的眼用產品
US12221494B2 (en) * 2019-08-27 2025-02-11 Mackay Memorial Hospital Short synthetic peptides and their uses for treating retinal degenerative diseases and/or tissue injuries
TWI744683B (zh) * 2019-08-27 2021-11-01 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 短合成胜肽及其治療視網膜退化性疾病和/或組織損傷的用途
CN115151243A (zh) * 2019-10-06 2022-10-04 全福生物科技股份有限公司 包含pedf-衍生短肽(pdsp)的组合物及其用途
CN112206312A (zh) * 2020-11-19 2021-01-12 北京大学第三医院（北京大学第三临床医学院） 一种包含pedf的用于治疗干眼的药物组合物
CN115364199A (zh) * 2021-05-19 2022-11-22 远大医药（中国）有限公司 包含pedf衍生的短肽的组合物及其制备方法和用途
KR20250023387A (ko) * 2022-06-13 2025-02-18 브림 바이오테크놀로지, 인코퍼레이티드 안구 건조증 질환 치료를 위한 pedf 유래 짧은 펩타이드를 포함하는 조성물
TW202400628A (zh) * 2022-06-24 2024-01-01 全福生物科技股份有限公司 用於治療神經營養性角膜炎疾病之包含pedf衍生短肽之組合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260180A1 (en) * 2004-03-12 2005-11-24 Genvec, Inc. Materials and methods for treating vascular leakage in the eye
US20130333068A1 (en) * 2008-04-29 2013-12-12 Marie Coffin Genes and uses for plant enhancement
US20150079094A1 (en) * 2013-09-13 2015-03-19 The Penn State Research Foundation Functional Peptide Analogs of PEDF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451763B1 (en) * 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
US6797691B1 (en) * 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
CN101014358A (zh) * 2003-10-29 2007-08-08 约翰·霍普金斯大学 色素上皮所衍生因子的生物活性及使用方法
US20090069241A1 (en) * 2006-02-15 2009-03-12 Yale University Compositions and Methods for Use of Pigment Epithelial Derived Factor (PEDF) Peptide Fragments
US20110111008A1 (en) * 2009-10-08 2011-05-12 Weng Tao Use of PEDF in an Encapsulated Cell-Based Delivery System
EP2508196B1 (en) * 2011-03-23 2018-09-26 Mackay Memorial Hospital Use of PEDF-derived polypeptides for promoting stem cells proliferation and wound healing
TWI554521B (zh) * 2011-10-19 2016-10-21 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 色素上皮衍生因子衍生之多胜肽於治療禿髮和／或毛髮脫色之用途
AU2012387503B2 (en) * 2012-08-09 2016-11-03 Mackay Memorial Hospital Use of PEDF-derived polypeptides for promoting muscle or tendon regeneration or arteriogenesis
AU2012390200B2 (en) * 2012-09-19 2017-06-29 Mackay Memorial Hospital Use of pedf-derived polypeptides for preventing and/or ameliorating skin aging
WO2014043871A1 (en) * 2012-09-20 2014-03-27 Yeou-Ping Tsao Use of pedf-derived polypeptides for treating osteoarthritis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260180A1 (en) * 2004-03-12 2005-11-24 Genvec, Inc. Materials and methods for treating vascular leakage in the eye
US20130333068A1 (en) * 2008-04-29 2013-12-12 Marie Coffin Genes and uses for plant enhancement
US20150079094A1 (en) * 2013-09-13 2015-03-19 The Penn State Research Foundation Functional Peptide Analogs of PEDF

Also Published As

Publication number Publication date
JP7573967B2 (ja) 2024-10-28
IL265796B2 (en) 2025-02-01
AU2022204557A1 (en) 2022-07-21
WO2018067217A2 (en) 2018-04-12
AU2017340245A1 (en) 2019-05-23
IL265796B1 (en) 2024-10-01
CN110312732A (zh) 2019-10-08
EP3596104A4 (en) 2021-02-17
WO2018067217A3 (en) 2019-05-02
EA201990885A1 (ru) 2019-08-30
US20190248859A1 (en) 2019-08-15
AU2017340245B2 (en) 2022-07-21
US11760784B2 (en) 2023-09-19
TW201822785A (zh) 2018-07-01
KR20190066030A (ko) 2019-06-12
WO2018067244A1 (en) 2018-04-12
KR20230169375A (ko) 2023-12-15
JP2022185042A (ja) 2022-12-13
JP2019533722A (ja) 2019-11-21
TWI878203B (zh) 2025-04-01
IL265796A (en) 2019-06-30
EP3596104A1 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
EA037698B1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
Upadhyay et al. Oxidative stress in the retina and retinal pigment epithelium (RPE): Role of aging, and DJ-1
Tang et al. Sleep deprivation induces dry eye through inhibition of PPARα expression in corneal epithelium
US20240123032A1 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
Lin et al. Serine protease inhibitor A3K suppressed the formation of ocular surface squamous metaplasia in a mouse model of experimental dry eye
JP2019065013A (ja) 軟骨細胞の細胞外基質由来ペプチド
Chaudhari et al. Rodent models for dry eye syndrome: Standardization using benzalkonium chloride and scopolamine hydrobromide
US20230348538A1 (en) Method for treatment of dry eye comprisng applying p55pik inhibitor
Li et al. Effects of topical mucolytic agents on the tears and ocular surface: a plausible animal model of mucin-deficient dry eye
WO2025162442A9 (zh) Kgf-2在治疗干眼症中的应用
Fernandez-Robredo et al. Azithromycin reduces inflammation in a rat model of acute conjunctivitis
KR102356603B1 (ko) 안구건조증 치료를 위한 레코플라본 함유 점안 조성물
TWI796875B (zh) 一種醫藥組合物用於製備眼表損傷之藥物的用途
JP2019525923A (ja) ドライアイ症候群を治療する方法
Lin et al. Comparison of 0.025% FK-506, 0.05% cyclosporin a, and 0.3% sodium hyaluronate eye drops for the treatment of botulinum toxin B-induced mouse dry eye
TWI698250B (zh) 短鏈胜肽組合物於預防或治療乾眼症之應用
EP3827814A1 (en) Ophthalmic formulations
Leah The deubiquitinase Otud7b suppresses cone photoreceptor cell degeneration in mouse models of retinal degenerative diseases
JP2025181979A (ja) 角膜の混濁および瘢痕化の予防および治療のための組成物および方法
Fernandez-Robredo et al. Azithromycin reduces inflammation in a rat model of acute conjunctivitis
HK40053198A (en) Ophthalmic formulations
CN118717959A (zh) Pedf多肽模拟物在眼表疾病中的用途
JP2007278819A (ja) 角結膜障害若しくは涙腺機能障害の治療薬、改善薬または予防薬のスクリーニング方法